Table 2 Overall assessment of benefits and practical challenges associated with switching from intravenous to subcutaneous or oral administration.

For	Against
Patient
Saving of time Greater flexibility in obtaining appointments Therapy can be integrated more easily in daily activities Original active pharmaceutical ingredient with verified efficacy and tolerability profile Prevents dosing errors Equivalent efficacy and tolerability of subcutaneous and intravenous trastuzumab	Better control with intravenous trastuzumab when administering therapy to cardiac high-risk patients
Center
Prevents dosing errors Prevents wastage Greater flexibility in making appointments Relieves pressures on the clinic in peak times Prevents overtime Compensates for a lack of staff Frees up capacity for intravenous therapies Competitive advantage over other centers which do not offer patients the benefit and the saving of time associated with subcutaneous trastuzumab administration	Overall working hours and time required identical, irrespective of the form of administration Reimbursement of subcutaneous trastuzumab is lower